BB Biotech (BION) Q2 2025 earnings summary

Executive summary

• Q2 2025 saw share price and NAV outperform the Nasdaq Biotech Index, with share price rising 10.2% in USD and NAV up 5.8% in USD, despite a turbulent macroeconomic environment, regulatory uncertainties, and currency effects.

• Major M&A activity included Sanofi's $9.5bn bid for Blueprint Medicines and Merck's $10bn offer for Verona Pharma, highlighting continued demand for innovation.

• Portfolio companies achieved significant clinical, regulatory, and commercial milestones, driving a sharp rebound in June after a weak start to the quarter and reinforcing the innovation-driven investment thesis.

• Active portfolio rotation included a full exit from Esperion Therapeutics and a new investment in Blueprint Medicines, with proceeds redeployed into higher-conviction holdings.

• The portfolio remains concentrated in 23 companies, with a focus on mid-cap innovators and a dynamic capital allocation strategy.

Financial highlights

• Net loss of CHF 341.2mn for H1 2025, with a Q2 2025 net loss of CHF 100mn, primarily driven by a 10.2% decline in USD/CHF exchange rate.

• NAV at period end: CHF 1,842.5mn, down from CHF 2,286.3mn at end-2024.

• Market capitalization at period end: CHF 1,673.1mn, down from CHF 1,961.2mn at end-2024.

• Earnings per share for H1 2025: CHF -6.24, compared to CHF 3.16 in H1 2024.

• Total expense ratio (TER) annualized at 1.39%.

Outlook and guidance

• Four key commercial launches expected in H2 2025, including Apitegromab, Donidalorsen, Mitapivat, and Troriluzole.

• Anticipated pivotal clinical readouts and proof-of-concept catalysts could drive further value.

• Management maintains a constructive but cautious outlook, citing ongoing policy and regulatory risks but highlighting accelerating innovation and attractive valuations.